Development asset linked to Denali Therapeutics in public FDA and regional records.
biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
Denali Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
Denali Therapeutics pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Denali Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Denali Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Histamine H2 receptor.
- Target
- Histamine H2 receptor
- Mechanism
- Histamine H2 receptor antagonist
-
idursulfase
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Heparan sulfate.
- Target
- Heparan sulfate
- Mechanism
- Heparan sulfate hydrolytic enzyme
-
Development asset linked to Denali Therapeutics in public FDA and regional records.
-
Development asset linked to Denali Therapeutics in public FDA and regional records.
-
Development asset linked to Denali Therapeutics in public FDA and regional records.
-
Development asset linked to Denali Therapeutics in public FDA and regional records.
-
US regulatory status: approved.